Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ingredient listing changes under FDA reform may be deferred until OTC label regs effective.

This article was originally published in The Tan Sheet

Executive Summary

OTC LABELING INGREDIENT LISTING CHANGES UNDER FDA REFORM MAY BE DEFERRED until companies bring their labeling into compliance with the agency's pending final rule on OTC drug labeling, the Center for Drug Evaluation & Research says in a guidance for industry issued Feb. 20. The FDA Modernization Act requires the name and quantity of each active and inactive ingredient appear on OTC drug labeling. Inactives must be listed on the outside container and, if deemed necessary, on the immediate container as well. If the OTC is not a "cosmetic-drug" (sunscreen, acne product, dandruff shampoo or antiperspirant/deodorant), the inactives must be listed in alphabetical order.
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS088123

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel